79
47
Growth Score
-6 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2069352
Epiva is a immuno-microbiome therapeutics platform.
- Simba Gill: CEOPast Role: Maxygen, Founder
Kareem Reda: Vice President Business Development & Strategy
About the Company
Epiva is an immuno-microbiome therapeutics platform.
Epiva is the next breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
As of July 12, 2016, Epiva Biosciences, Inc. was acquired by Evelo Biosciences. Epiva Biosciences, Inc. develops immunobiotic therapeutics, a class of primed bacterial
interventions designed to restore normo-biosis, the microbiome signature normally found in healthy people. It focuses on treating conditions characterized by inflammation and aberrant immune responses by modulating the systemic microbiome, the host immune-bacteria interface. The company was founded in 2015 and is based in Cambridge, Massachusetts.
